Gadolinium Lawsuit | Gadolinium Deposition Disease
Free Consultations • Available 24/7
Legal Representation for Victims of Gadolinium Toxicity and Gadolinium Deposition Disease
Gadolinium-based contrast agents (Gadolinium Toxicity Lawsuits) are injected into a vein to enhance the quality of magnetic resonance imaging (MRI). Since 2006, medical communities and patients began questioning the safety of GBCAs. Since its FDA approval in 1987, various medical issues have come to light concerning Gadolinium’s use in MRIs. Gadolinium lawsuits have been filed as more patients come forward with Gadolinium Deposition Disease symptoms. In fact, in December 2017, the U.S. Food and Drug Administration began requiring a new class warning and other safety measures for gadolinium-based contrast agents used in magnetic resonance imaging (MRI). The move came after years of studies showed deposits of gadolinium found in the brain and other organs in the body. After a gadolinium injection, patients may notice persistent health problems. Patients who believe they are living with Gadolinium Deposition Disease should contact The Carlson Law firm to speak with a qualified Gadolinium lawyer.
The Gadolinium lawsuit stems from a growing number of patients who have undergone an MRI and reporting subsequent illnesses. We have helped clients all over the country recover millions of dollars in settlements from similar defective medical products. More importantly, The Carlson Law Firm has more than 40 years of experience helping clients dealing with personal injuries stemming from defective products. Contact The Carlson Law Firm for a free consultation to speak with a qualified Gadolinium Lawyer to discuss your case. Learn more about Gadolinium Deposition Disease below.
Gadolinium retention is the persistence of gadolinium in the body for a period of time exceeding the standard expulsion. High retention rates of gadolinium have been found mostly in linear brands of the drug. With normal functioning kidneys, the bulk of gadolinium injected should be expelled from the body through urine and feces within two hours. The rest of the substance is expelled over the next few days—within 96 hours. However, studies have shown that some forms of GBCAs persist in the body’s organs, such as the brain, skin, and bones, for months to years after receiving the drug.
Until 2006, the main considerations regarding safety for all gadolinium-based contrast agents were related to short-term adverse reactions. However, in the last 10 years, studies have shown that prolonged, elevated level of gadolinium in the body.
Gadolinium has been linked to the following medical conditions:
Nephrogenic Systemic Fibrosis: develops from linear GBCAs in patients with poor renal function. Thickening and scarring of connective tissues in the skin, joints, eyes and internal organs indicate the development of the condition.
Gadolinium Deposition Disease: develops in patients with healthy kidney function. GDD is the development of persistent and painful symptoms for a few hours or weeks after receiving a GBCA injection.
Gadolinium Storage Condition: develops in patients with healthy renal function. However, traces of gadolinium remain in the brain, tissue, bones or other parts of the body.
The Carlson Law Firm is currently accepting clients suffering from Gadolinium Deposition Disease. If you believe you a GBCA from an MRI is the source of your pain, you may be eligible to receive compensation from the Gadolinium Lawsuit. Our firm has a Gadolinium lawyer that can help you file your claim.
What is Gadolinium Deposition Disease?
Gadolinium Deposition Disease (GDD) is an incurable disease linked to the use of gadolinium-based contrast agents during MRI procedures. GDD refers to a patient who experiences persistent medical symptoms that arise even after just one dose of GBCA. The symptoms may last for a few hours to for two months or longer. In cases of GDD, no preexistent disease or subsequently developed disease is present to account for symptoms.
Exposure to gadolinium-based contrast agents has adverse side effects. Patients with Gadolinium Deposition Disease describe the following symptoms:
- Persistent burning or cutting sensation in the lower arms and lower limbs.
- Pain in bones and joints
- Head and neck pain
- Tightness in hands and feet
- Mental confusion, or brain fog
- Persistent headaches
- Vision and hearing problems
- Loss of hair
- Itchy skin
- Breathing problems
Additionally, in later stages, victims report skin problems such as progressive skin thickening and discoloration. If you are suffering from any of these symptoms, contact The Carlson Law Firm. You may be eligible for compensation from the Gadolinium Lawsuit. Our firm has a Gadolinium lawyer that can help you file your claim.
Is Gadolinium toxic?
Yes. Gadolinium is a toxic naturally occurring element on the Periodic Table as Gd, atomic number 64. It is a soft, heavy metal classified as a rare Earth element of the lanthanide series. In the medical field, the substance’s primary use is as a magnetic resonance imaging contrast media or dye. Because the Gadolinium is toxic, the agent is coated—or linked—to another chemical to protect the body from its toxic effects when injected for MRIs.
Linking compounds come in two forms:
- Linear: ineffectively covers gadolinium, thus exposing patients to the element’s toxicity.
- Spherical (Macrocyclic): An improved gadolinium-based contrast agent that more effectively covers gadolinium.
Consequently, if you are experiencing Gadolinium Deposition Disease, you were likely exposed to the chemical linked to the linear compound. The version of the drug that does a poor job covering the toxic chemical to prevent exposure in the body. Those receiving the linear doses risk exposure to Gadolinium’s toxicity and retention. Additionally, they may now experience painful GDD symptoms. Linear gadolinium-based contrast agents result in higher levels of gadolinium that lasts in the body for far longer periods than spherical linking compounds.
Where does the U.S. FDA Stand on Gadolinium?
Despite numerous warnings released by the U.S. Food and Drug Administration (FDA), the FDA concluded that the benefits of approved GBCAs outweigh any potential risks. While the European Pharmacovigilance Risk Assessment Committee (EPRAC)—the European equivalent to the FDA—has suspended or restricted use of linear GBCAs, the FDA has not given any indicators that it will pull the drug from U.S. shelves.
On May 16, 2018, the FDA issued a non-actionable update to its December 2017 Safety Announcement; which required a new class warning and other safety measures for all GBCAs. Additionally, the 2017 update required specific changes to the labeling of all GBCAs:
- A warning and precaution
- Changes related to gadolinium retention in the Adverse Reactions, Pregnancy, Clinical Pharmacology and Patient Instructions sections
The 2018 update approves a new patient Medication Guide for outpatients receiving a GBCA injection for the first time. The guide’s intent is to alert patients that they may retain some level of the heavy metal for months to years after receiving just one dose of a GBCA. FDA guidelines do not require doctors to discuss the drug with patients. Additionally, medical professionals must give the guide to patients who request more information on GBCAs. However, healthcare professionals who determine that the medication guide is not in the best interest of a patient may decline to provide the guide—unless the patient asks.
In the meantime, the FDA states on its website that it is continuing to monitor the health effects of gadolinium retention.
Gadolinium-Based Contrast Agents
All patients exposed to GBCAs are at risk of Gadolinium retention. In fact, researchers have estimated that approximately 1 percent of the 1.5 grams of injected gadolinium remain and deposited into the bones of patients with normal kidney function.
As of 2017, there were eight Gadolinium-based contrast agents commercially marketed and sold in the U.S. The substance is available in both brand name and generic forms. The FDA issued a Safety Announcement in 2017 stating that it had not changed its recommendations to patients or healthcare professionals on gadolinium-based contrast agents.
Of the eight brands, OptiMark and Omniscan have the highest gadolinium levels remaining in the body. On the other hand, gadolinium levels were the lowest in ProHance, Gadavist and Dotarem.
If you received an MRI and are now experiencing symptoms of GDD, contact our firm today. We can schedule a free consultation with a gadolinium lawyer to discuss your options for the Gadolinium Lawsuit.
How does Chuck Norris fit into the Gadolinium Lawsuit?
Because of the frequency and nature of MRIs, the effects of gadolinium retention are far and wide. A California-based law firm filed a lawsuit on behalf of Chuck and Gena Norris on November 2, 2017.
The action star and his wife are suing 11 drug companies for $10 million, alleging his wife was poisoned by gadolinium from her MRIs. The lawsuit goes on to say the Gena was a healthy, athletic woman with normal kidney function. However, over an eight-day period, she underwent three MRIs. She received linear MultiHance and the spherical ProHance injections. Three days later, Gena felt sick and was rushed to the hospital—describing a burning sensation in her abdomen.
The Norrises report spending more than $2 million to diagnose and treat Gena’s GDD condition.
Gena wrote to the FDA Medical Imaging Drugs Advisory Committee Meeting:
“After almost five years of dealing with this condition, which has only recently become known as Gadolinium Deposition Disease, it is difficult for me to recount this ordeal. It brings back horrific memories that I have tried to block out, but some things I cannot forget.”
The Norrises say that companies should have warned them of risks associated with the drug. Chuck and his wife, Gena, say that she has gadolinium deposition disease stemming from MRIs she had more than six years ago.
The Norrises say they are lending their celebrity voices on behalf of thousands of others victims who have gone largely ignored. They are suing pharmaceutical distributor McKesson Corp. and the diagnostics, research and imaging arms of the Italian health-care company Bracco S.P.A.
A Gadolinium Lawyer From The Carlson Law Firm Can Help
The Carlson Law Firm believes in holding drug manufacturers accountable for their actions. Additionally, they have a responsibility to take steps to warn patients of the risks associated with their products. Instead, these companies often put profit over people. For years, the makers of gadolinium-based contrast agents may have been aware of the risks associated with the MRI drug. However, the continuously failed to warn the public. As a result, people are suffering from rare, incurable conditions such as Gadolinium Deposition Disease.
If you or anyone you know has unexplained symptoms after an MRI, contact a Gadolinium lawyer right away. The Carlson Law Firm can help you get the medical assistance you need to relieve your persistent symptoms from Gadolinium Deposition Disease or other incurable diseases.
Contact our firm to schedule a free consultation with a Gadolinium lawyer to discuss Gadolinium Deposition Disease today.